{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T14:42:51Z","timestamp":1793457771718,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["JP21nf0101637"],"award-info":[{"award-number":["JP21nf0101637"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["JP21nf0101637"],"award-info":[{"award-number":["JP21nf0101637"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["JP21nf0101637"],"award-info":[{"award-number":["JP21nf0101637"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-00054-x","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T12:06:49Z","timestamp":1748434009000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prolonged effects of adenoviral vector priming on T-cell cytokine production in heterologous adenoviral vector\/mRNA COVID-19 vaccination regimens"],"prefix":"10.1038","volume":"15","author":[{"given":"Masanori","family":"Isogawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taishi","family":"Onodera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Ainai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryutaro","family":"Kotaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Kanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Tobiume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenzo","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Hirota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadaki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimasa","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Tsuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"key":"54_CR1","doi-asserted-by":"publisher","first-page":"abm0829","DOI":"10.1126\/science.abm0829","volume":"374","author":"RR Goel","year":"2021","unstructured":"Goel, R. R. et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science 374, abm0829 (2021).","journal-title":"Science"},{"key":"54_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.08.001","author":"MM Painter","year":"2021","unstructured":"Painter, M. M. et al. Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination. Immunity https:\/\/doi.org\/10.1016\/j.immuni.2021.08.001 (2021).","journal-title":"Immunity"},{"key":"54_CR3","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41586-021-04060-7","volume":"600","author":"A Cho","year":"2021","unstructured":"Cho, A. et al. Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. Nature 600, 517\u2013522 (2021).","journal-title":"Nature"},{"key":"54_CR4","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1016\/j.immuni.2021.09.011","volume":"54","author":"A Sokal","year":"2021","unstructured":"Sokal, A. et al. mRNA vaccination of Naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants. Immunity 54, 2893\u20132907 (2021).","journal-title":"Immunity"},{"key":"54_CR5","doi-asserted-by":"crossref","unstructured":"Mazzoni, A. et al. First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19. J. Clin. Invest. 131, e149150 (2021).","DOI":"10.1172\/JCI149150"},{"key":"54_CR6","doi-asserted-by":"publisher","first-page":"4969","DOI":"10.1016\/j.cell.2021.07.025","volume":"184","author":"P Tong","year":"2021","unstructured":"Tong, P. et al. Memory B cell repertoire for recognition of evolving SARS-CoV-2 Spike. Cell 184, 4969\u20134980 (2021).","journal-title":"Cell"},{"key":"54_CR7","doi-asserted-by":"publisher","first-page":"eabi6950","DOI":"10.1126\/sciimmunol.abi6950","volume":"6","author":"RR Goel","year":"2021","unstructured":"Goel, R. R. et al. Distinct antibody and memory B cell responses in SARS-CoV-2 Na\u00efve and recovered individuals following mRNA vaccination. Sci. Immunol. 6, eabi6950 (2021).","journal-title":"Sci. Immunol."},{"key":"54_CR8","doi-asserted-by":"crossref","unstructured":"Mateus, J. et al. Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells. Science eabj9853 (2021).","DOI":"10.1101\/2021.06.30.21259787"},{"key":"54_CR9","doi-asserted-by":"crossref","unstructured":"Kotaki, R. et al. SARS-CoV-2 Omicron-neutralizing memory B-cells are elicited by two doses of BNT162b2 mRNA vaccine. Sci. Immunol. eabn8590 (2022).","DOI":"10.1126\/sciimmunol.abn8590"},{"key":"54_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100631","author":"T Takano","year":"2022","unstructured":"Takano, T. et al. Distinct immune cell dynamics correlate with the immunogenicity and reactogenicity of SARS-CoV-2 mRNA vaccine. Cell. Rep. Med. https:\/\/doi.org\/10.1016\/j.xcrm.2022.100631 (2022).","journal-title":"Cell. Rep. Med."},{"key":"54_CR11","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"54_CR12","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"54_CR13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1126\/science.abm3425","volume":"375","author":"PB Gilbert","year":"2022","unstructured":"Gilbert, P. B. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 375, 43\u201350 (2022).","journal-title":"Science"},{"key":"54_CR14","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","volume":"39","author":"KA Earle","year":"2021","unstructured":"Earle, K. A. et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 39, 4423\u20134428 (2021).","journal-title":"Vaccine"},{"key":"54_CR15","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211 (2021).","journal-title":"Nat. Med."},{"key":"54_CR16","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.vaccine.2023.12.033","volume":"42","author":"T Arashiro","year":"2024","unstructured":"Arashiro, T. et al. COVID-19 vaccine effectiveness against severe COVID-19 requiring oxygen therapy, invasive mechanical ventilation, and death in Japan: A multicenter case-control study (MOTIVATE study). Vaccine 42, 677\u2013688 (2024).","journal-title":"Vaccine"},{"key":"54_CR17","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","volume":"384","author":"NH Schultz","year":"2021","unstructured":"Schultz, N. H. et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N. Engl. J. Med. 384, 2124\u20132130 (2021).","journal-title":"N. Engl. J. Med."},{"key":"54_CR18","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","volume":"384","author":"A Greinacher","year":"2021","unstructured":"Greinacher, A. et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N. Engl. J. Med. 384, 2092\u20132101 (2021).","journal-title":"N. Engl. J. Med."},{"key":"54_CR19","doi-asserted-by":"publisher","first-page":"100249","DOI":"10.1016\/j.lanepe.2021.100249","volume":"11","author":"P Nordstr\u00f6m","year":"2021","unstructured":"Nordstr\u00f6m, P., Ballin, M. & Nordstr\u00f6m, A. Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study. Lancet Reg. Health Eur. 11, 100249 (2021).","journal-title":"Lancet Reg. Health Eur."},{"key":"54_CR20","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41586-021-04120-y","volume":"600","author":"B Pozzetto","year":"2021","unstructured":"Pozzetto, B. et al. Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination. Nature 600, 701\u2013706 (2021).","journal-title":"Nature"},{"key":"54_CR21","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3390\/vaccines12080883","volume":"12","author":"K Shoemaker","year":"2024","unstructured":"Shoemaker, K. et al. Long-term safety and immunogenicity of AZD1222 (ChAdOx1 nCoV-19): 2-year follow-up from a phase 3 study. Vaccines 12, 883 (2024).","journal-title":"Vaccines"},{"key":"54_CR22","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41586-020-2852-1","volume":"588","author":"CO Barnes","year":"2020","unstructured":"Barnes, C. O. et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature 588, 682\u2013687 (2020).","journal-title":"Nature"},{"key":"54_CR23","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41586-020-2548-6","volume":"584","author":"SJ Zost","year":"2020","unstructured":"Zost, S. J. et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature 584, 443\u2013449 (2020).","journal-title":"Nature"},{"key":"54_CR24","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","volume":"183","author":"L Piccoli","year":"2020","unstructured":"Piccoli, L. et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell 183, 1024\u20131042e21 (2020).","journal-title":"Cell"},{"key":"54_CR25","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1126\/science.abc7520","volume":"369","author":"TF Rogers","year":"2020","unstructured":"Rogers, T. F. et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science 369, 956\u2013963 (2020).","journal-title":"Science"},{"key":"54_CR26","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1016\/j.cell.2021.02.035","volume":"184","author":"E Andreano","year":"2021","unstructured":"Andreano, E. et al. Extremely potent human monoclonal antibodies from COVID-19 convalescent patients. Cell 184, 1821\u20131835 (2021).","journal-title":"Cell"},{"key":"54_CR27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cell.2020.05.025","volume":"182","author":"Y Cao","year":"2020","unstructured":"Cao, Y. et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients\u2019 B cells. Cell 182, 73\u201384 (2020).","journal-title":"Cell"},{"key":"54_CR28","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1056\/NEJMoa2115463","volume":"386","author":"BA Dickerman","year":"2022","unstructured":"Dickerman, B. A. et al. Comparative effectiveness of BNT162b2 and mRNA-1273 vaccines in US Veterans. N. Engl. J. Med. 386, 105\u2013115 (2022).","journal-title":"N Engl. J. Med."},{"key":"54_CR29","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.medj.2021.12.002","volume":"3","author":"A Puranik","year":"2022","unstructured":"Puranik, A. et al. Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection. Med 3, 28\u201341e8 (2022).","journal-title":"Med"},{"key":"54_CR30","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMc2117933","volume":"386","author":"LJ Abu-Raddad","year":"2022","unstructured":"Abu-Raddad, L. J., Chemaitelly, H., Bertollini, R. & National Study Group for COVID-19 Vaccination. Effectiveness of mRNA-1273 and BNT162b2 vaccines in Qatar. N. Engl. J. Med. 386, 799\u2013800 (2022).","journal-title":"N. Engl. J. Med."},{"key":"54_CR31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1359-6101(97)00034-8","volume":"9","author":"K Takatsu","year":"1998","unstructured":"Takatsu, K. Interleukin 5 and B cell differentiation. Cytokine Growth Factor Rev. 9, 25\u201335 (1998).","journal-title":"Cytokine Growth Factor Rev."},{"key":"54_CR32","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/312641a0","volume":"312","author":"MC Mingari","year":"1984","unstructured":"Mingari, M. C. et al. Human interleukin-2 promotes proliferation of activated B cells via surface receptors similar to those of activated T cells. Nature 312, 641\u2013643 (1984).","journal-title":"Nature"},{"key":"54_CR33","doi-asserted-by":"publisher","first-page":"161","DOI":"10.4049\/jimmunol.1200301","volume":"189","author":"S Le Gallou","year":"2012","unstructured":"Le Gallou, S. et al. IL-2 requirement for human plasma cell generation: Coupling differentiation and proliferation by enhancing MAPK-ERK signaling. J. Immunol. 189, 161\u2013173 (2012).","journal-title":"J. Immunol."},{"key":"54_CR34","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1038\/s41467-017-01475-7","volume":"8","author":"N Hipp","year":"2017","unstructured":"Hipp, N. et al. IL-2 imprints human Naive B cell fate towards plasma cell through ERK\/ELK1-mediated BACH2 repression. Nat. Commun. 8, 1443 (2017).","journal-title":"Nat. Commun."},{"key":"54_CR35","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.immuni.2009.05.001","volume":"30","author":"L Zhou","year":"2009","unstructured":"Zhou, L., Chong, M. M. W. & Littman, D. R. Plasticity of CD4+ T cell lineage differentiation. Immunity 30, 646\u2013655 (2009).","journal-title":"Immunity"},{"key":"54_CR36","doi-asserted-by":"publisher","first-page":"630","DOI":"10.3389\/fimmu.2014.00630","volume":"5","author":"J Geginat","year":"2014","unstructured":"Geginat, J. et al. Plasticity of human CD4 T cell subsets. Front. Immunol. 5, 630 (2014).","journal-title":"Front. Immunol."},{"key":"54_CR37","doi-asserted-by":"publisher","unstructured":"Murphy, D. M. et al. Trained immunity is induced in humans after immunization with an adenoviral vector COVID-19 vaccine. J. Clin. Invest.. https:\/\/doi.org\/10.1172\/JCI162581 (2023).","DOI":"10.1172\/JCI162581"},{"key":"54_CR38","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1128\/CVI.00131-10","volume":"17","author":"SA Plotkin","year":"2010","unstructured":"Plotkin, S. A. Correlates of protection induced by vaccination. Clin. Vaccine Immunol. 17, 1055\u20131065 (2010).","journal-title":"Clin. Vaccine Immunol."},{"key":"54_CR39","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV Spike in the prefusion conformation. Science 367, 1260\u20131263 (2020).","journal-title":"Science"},{"key":"54_CR40","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-020-2607-z","volume":"586","author":"NB Mercado","year":"2020","unstructured":"Mercado, N. B. et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature 586, 583\u2013588 (2020).","journal-title":"Nature"},{"key":"54_CR41","doi-asserted-by":"publisher","first-page":"eadp9927","DOI":"10.1126\/scitranslmed.adp9927","volume":"16","author":"R Kotaki","year":"2024","unstructured":"Kotaki, R. et al. Repeated Omicron exposures redirect SARS-CoV-2-specific memory B cell evolution toward the latest variants. Sci. Transl. Med. 16, eadp9927 (2024).","journal-title":"Sci. Transl. Med."},{"key":"54_CR42","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1016\/j.immuni.2021.06.015","volume":"54","author":"S Moriyama","year":"2021","unstructured":"Moriyama, S. et al. Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants. Immunity 54, 1841\u20131852 (2021).","journal-title":"Immunity"},{"key":"54_CR43","doi-asserted-by":"publisher","first-page":"eadf0661","DOI":"10.1126\/sciadv.adf0661","volume":"9","author":"T Onodera","year":"2023","unstructured":"Onodera, T. et al. CD62L expression marks SARS-CoV-2 memory B cell subset with preference for neutralizing epitopes. Sci. Adv. 9, eadf0661 (2023).","journal-title":"Sci. Adv."},{"key":"54_CR44","doi-asserted-by":"publisher","first-page":"104959","DOI":"10.1016\/j.isci.2022.104959","volume":"25","author":"K Terahara","year":"2022","unstructured":"Terahara, K. et al. SARS-CoV-2-specific CD4+ T cell longevity correlates with Th17-like phenotype. iScience 25, 104959 (2022).","journal-title":"iScience"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00054-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00054-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00054-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T12:06:51Z","timestamp":1748434011000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00054-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["54"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-00054-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,28]]},"assertion":[{"value":"5 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18684"}}